Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042480 · ClinicalTrials.gov registry record · Phase 1
A Study of SGN-CD228A in Advanced Solid Tumors
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04042480 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 88 participants.
The verdict
NCT04042480, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
Interventions
- DRUG SGN-CD228A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2023-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042480
The ClinicalTrials.gov registry entry for NCT04042480 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD228A is the first listed.
NCT04042480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04042480 about?
NCT04042480 is a clinical study titled "A Study of SGN-CD228A in Advanced Solid Tumors". This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and...
What is the current status of trial NCT04042480?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2019-09-03. Estimated completion is 2023-03-09.
What interventions are being tested in trial NCT04042480?
The interventions under investigation include: SGN-CD228A (DRUG).
Who is sponsoring clinical trial NCT04042480?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.